Regenerative performance and immunogenicity of engineered extracellular matrices.
Critical-sized bone defects remain a significant unmet clinical need, with > 500,000 reconstructive procedures performed annually in the United States and Europe and associated costs exceeding US$3 billion. Autologous bone grafting—the current gold standard—suffers from limited harvest volume and donor-site morbidity, whereas allografts show variable integration and carry immunological and infecti
